Jonathan Lee Halperin

Jonathan Lee Halperin's AcademicInfluence.com Rankings

Medical

#1352

World Rank

#1679

Historical Rank

Cardiology

#96

World Rank

#98

Historical Rank

medical Degrees

Download Badge

Medical

Jonathan Lee Halperin's Degrees

Doctorate Medicine Harvard University

Why Is Jonathan Lee Halperin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jonathan Lee Halperin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014) (6648)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. (2011) (5296)
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article (2005) (5001)
Edoxaban versus warfarin in patients with atrial fibrillation. (2013) (3988)
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography (2006) (3207)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC (2006) (2631)
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006) (2558)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (2552)
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker (2008) (2315)
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie (2007) (1962)
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014) (1905)
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014) (1904)
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference (2001) (1865)
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). (2004) (1807)
Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the (2006) (1582)
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker (2008) (1569)
Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. (2011) (1539)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention (2006) (1467)
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. (2001) (1444)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006) (1406)
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiov (2007) (1400)
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2008) (1319)
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2010) (1269)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). (2006) (1197)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. (2016) (1176)
[Guidelines for the management of patients with atrial fibrillation. Executive summary]. (2006) (1171)
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary (2010) (1162)
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial (1996) (1081)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ (2006) (1079)
ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation (2007) (1064)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013) (1053)
ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Intervent (2006) (1040)
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (1008)
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Ang (2006) (1006)
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (982)
Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the (2006) (977)
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. (2011) (970)
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2008) (927)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (888)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (880)
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. (2008) (872)
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemaker (2008) (866)
2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the Europe (2011) (860)
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2008) (847)
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. (2003) (830)
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (789)
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text (2006) (778)
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. (2005) (722)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). (2006) (709)
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. (2014) (696)
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention (2013) (682)
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. (2000) (671)
A pharmacogenetic versus a clinical algorithm for warfarin dosing. (2013) (667)
Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. (2001) (647)
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (640)
Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. (1992) (636)
ACCF / AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults (2010) (636)
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (609)
2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (605)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011) (591)
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (590)
Reprint: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. (2013) (583)
Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (579)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline (2011) (559)
Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. (1998) (518)
Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort (2010) (495)
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (2013) (493)
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. (2008) (490)
Guide to Anticoagulant Therapy: Heparin: A Statement for Healthcare Professionals From the American Heart Association (2001) (441)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline (2011) (441)
Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial (2013) (427)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2011) (426)
[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. (2006) (412)
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (396)
[ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. (2006) (378)
Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease (2010) (378)
Dronedarone in high-risk permanent atrial fibrillation. (2011) (368)
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. (2014) (348)
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). (1999) (339)
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF (2012) (335)
Subclinical atrial fibrillation and the risk of stroke. (2012) (324)
Atrial fibrillation and stroke : concepts and controversies. (2001) (323)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (321)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2011) (317)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention (2006) (315)
Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. (2015) (306)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. (2011) (301)
Thoracic aortic aneurysm and dissection. (2014) (290)
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial (2008) (289)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. (2011) (288)
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. (2013) (286)
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial (2014) (281)
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2013) (277)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary (2016) (266)
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2012) (256)
Lessons from the Stroke Prevention in Atrial Fibrillation Trials (2003) (256)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American (2011) (253)
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. (2017) (252)
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidel (2006) (244)
Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2011) (237)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study (2013) (232)
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial (2013) (231)
AHA/ACC Scientific StatementAmerican Heart Association/American College of Cardiology Foundation guide to warfarin therapy1 (2003) (231)
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. (2014) (229)
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention) (2006) (226)
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. (2021) (225)
Atrial fibrillation and stroke: new ideas, persisting dilemmas. (1988) (219)
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). (2014) (215)
Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). (2003) (213)
Mechanism of action and pharmacology of unfractionated heparin. (2001) (213)
Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. (2013) (211)
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2012) (208)
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. (2006) (201)
The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2014) (193)
Improving stroke risk stratification in atrial fibrillation. (2010) (190)
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (2018) (190)
Acute Regional Circulatory and Renal Hemodynamic Effects of Converting‐enzyme Inhibition in Patients with Congestive Heart Failure (1981) (188)
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study (2017) (184)
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline) (2011) (184)
Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease (2006) (182)
Early management of atrial fibrillation to prevent cardiovascular complications. (2014) (182)
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial (2014) (177)
ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Wr (2008) (174)
OCT-based diagnosis and management of STEMI associated with intact fibrous cap. (2013) (174)
Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (2014) (173)
Risk of Thromboembolism in Heart Failure: An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (2007) (169)
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (166)
Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. (2015) (163)
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. (2014) (162)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary (2011) (162)
Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. (2000) (162)
Deep learning for cardiovascular medicine: a practical primer. (2019) (161)
Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators. (1999) (157)
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. (2015) (157)
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. (2015) (151)
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). (2004) (151)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary (2012) (149)
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation (2008) (146)
Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. (2019) (144)
AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. (2014) (138)
Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia (2020) (138)
2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 guideline) (2012) (138)
2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary (2017) (137)
ACCF/AHA Clinical Practice Guideline Methodology Summit Report: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) (136)
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial (2018) (133)
Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation (1995) (133)
Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). (1999) (132)
Atrial fibrillation--risk marker for stroke. (1990) (132)
Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. (1999) (130)
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective (2013) (130)
AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. (2014) (129)
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation (2016) (127)
Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial (2013) (124)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary (2011) (123)
Machine learning prediction in cardiovascular diseases: a meta-analysis (2020) (121)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (119)
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (115)
Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. (2009) (115)
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). (2010) (115)
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. (2017) (114)
Left ventricular thrombi and cerebral embolism. (1989) (113)
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. (2014) (112)
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). (2015) (112)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (2016) (111)
Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. (1989) (109)
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation: Insights From ROCKET AF (2013) (106)
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. (1981) (106)
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. (2003) (105)
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. (2009) (105)
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. (2000) (104)
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. (2006) (104)
ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (103)
Determinants of clinical response and survival in patients with congestive heart failure treated with captopril. (1982) (102)
Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial (2014) (99)
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy (2017) (98)
ACCF/AHA/SCAI 2013 Update of the Clinical Competence Statement on Coronary Artery Interventional Procedures (2013) (97)
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF (2014) (90)
Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. (2015) (86)
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry (2017) (84)
Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. (1993) (84)
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. (2014) (83)
Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. (2012) (83)
Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. (2003) (83)
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. (2013) (83)
ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and So (2019) (82)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2016) (81)
Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy (2016) (80)
COCATS 4 Introduction. (2015) (75)
Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. (2013) (75)
ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Wr (2008) (74)
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes (2015) (74)
Evaluation of patients with peripheral vascular disease. (2002) (73)
Present use of bedside right heart catheterization in patients with cardiac disease (1998) (73)
Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (71)
ACCF/AHA Focused Update 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (2011) (71)
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. (2014) (69)
A Medical Perspective (1994) (68)
Atrial fibrillation and stroke. Revisiting the dilemmas. (1994) (66)
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE (2016) (66)
ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3) (2015) (66)
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management (2020) (65)
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF (2018) (64)
Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. (1999) (63)
Central and Peripheral Hemodynamic Effects of Angiotensin Inhibition in Patients with Refractory Congestive Heart Failure (1980) (62)
Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force. (2006) (62)
Interaction Between Digoxin and Dronedarone in the PALLAS Trial (2014) (61)
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy (2013) (61)
Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. (1995) (61)
Pathophysiology of Raynaud's disease. (1979) (59)
Atherosclerotic Vascular Disease Conference: Writing Group V: medical decision making and therapy. (2004) (56)
Guide to Anticoagulant Therapy: Heparin (2001) (56)
Aspirin in the prevention of coronary disease. (1989) (55)
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (55)
Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. (2006) (54)
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort (2016) (52)
The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease. (1982) (52)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary (2011) (50)
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. (2016) (50)
Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial (2012) (49)
Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches? (2014) (49)
Atrial Fibrillation in Patients Hospitalized With COVID-19 (2021) (49)
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. (1990) (48)
AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. (2001) (48)
A proposal for new clinical concepts in the management of atrial fibrillation. (2012) (48)
Device-detected atrial fibrillation: what to do with asymptomatic patients? (2015) (47)
Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. (1982) (46)
Should patients with atrial fibrillation be anticoagulated prior to and chronically following cardioversion? (1990) (46)
End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience (2013) (46)
Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. (2005) (45)
Patent foramen ovale and recurrent stroke: another paradoxical twist. (2002) (45)
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. (2014) (44)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. (2016) (44)
Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study. (1998) (44)
Malignant Arrhythmias in Patients With COVID-19 (2020) (43)
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. (2017) (40)
Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial (2012) (40)
Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. (2022) (39)
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (2016) (38)
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients (2020) (38)
Aortic regurgitation: disease progression and management (2008) (37)
The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014) (37)
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. (2016) (36)
Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. (2014) (36)
Prevention of stroke in patients with atrial fibrillation. (2008) (36)
Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure. (1984) (35)
Radiation Safety in the Practice of Cardiology WRITING GROUP MEMBERS (1998) (34)
Pro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions’ (2008) (33)
Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges (2007) (33)
Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). (2015) (32)
AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy : Executive summary (2011) (32)
Aortic dissection: a medical perspective. (1994) (31)
The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. (2017) (31)
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). (2017) (31)
"Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. (2008) (31)
Antithrombotic therapy in cardiac disease: an approach based on pathogenesis and risk stratification. (1990) (30)
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation (2016) (30)
2016 ACC Lifelong Learning Competencies for General Cardiologists: A Report of the ACC Competency Management Committee. (2016) (29)
Obliteration of the left atrial appendage for prevention of thromboembolism. (2003) (29)
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF (2016) (29)
Obliteration of the leftatrial appendage forprevention of thromboembolism (2003) (28)
Associations of LV hypertrophy with prevalent and incident valve calcification: Multi-Ethnic Study of Atherosclerosis. (2012) (27)
Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial (2012) (27)
Elevated homocysteine levels in patients with end-stage renal disease. (2005) (27)
The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review (2017) (26)
Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants (2008) (26)
Association between troponin I levels and mortality in stable hemodialysis patients. (2003) (25)
Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review. (2022) (25)
Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillations. (1988) (25)
The Prevalence and One‐year Outcome of Limb Arterial Obstructive Disease in a Nursing Home Population (1988) (25)
Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. (2018) (24)
Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group. (1986) (24)
COCATS 4 Task Force 1: Training in Ambulatory, Consultative, and Longitudinal Cardiovascular Care. (2015) (24)
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. (2017) (24)
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. (2016) (23)
Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. (2018) (23)
Trials and tribulations of noninferiority: the ximelagatran experience. (2006) (23)
Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes (2020) (23)
Nitroglycerin therapy in the management of pulmonary hypertensive disorders. (1984) (22)
Digital vasodilatation during mental stress in patients with Raynaud's disease. (1983) (22)
New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation (2011) (22)
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry (2017) (22)
Rate or rhythm control for atrial fibrillation: update and controversies. (2012) (21)
Postgraduate training in vascular medicine: proposed requirements and standards (2003) (21)
Myopotential interference with DDD pacemakers: endocardial electrographic telemetry in the diagnosis of pacemaker-related arrhythmias. (1984) (21)
Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. (2014) (21)
Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2012) (20)
2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). (2015) (20)
(8th Edition) Evidence-Based Clinical Practice Guidelines American College of Chest Physicians Antithrombotic Therapy in Atrial Fibrillation: (2008) (20)
Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty (2012) (20)
Machine learning and deep learning to predict mortality in patients with spontaneous coronary artery dissection (2021) (20)
Two‐year follow‐up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long‐Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA‐AF) registry (2018) (20)
Regional circulatory response to converting-enzyme inhibition in congestive heart failure. (1982) (19)
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American (2011) (19)
Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT). (2016) (18)
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. (2017) (18)
Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. (2012) (18)
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. (2011) (18)
USE AND OUTCOMES OF ANTIARRHYTHMIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULATION: RESULTS FROM THE ROCKET AF TRIAL (2014) (18)
Meeting the challenge of peripheral arterial disease. (2003) (17)
Cardiovascular risk and complications associated with COVID-19. (2020) (17)
Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. (2017) (17)
Prevention of stroke in patients with atrial fibrillation (2005) (17)
Anticoagulation in patients with heart failure: who, when, and why? (2006) (16)
Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society (2011) (16)
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial (2015) (16)
Oral anticoagulants in the management of venous thromboembolism (2013) (16)
Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program (2018) (16)
Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world (2021) (16)
Effect of nitroglycerin on the pulmonary venous gradient in patients after mitral valve replacement. (1985) (16)
2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee. (2019) (16)
Thromboembolism in nonvalvular atrial fibrillation: the answer may be in the ventricle. (1992) (15)
Thromboembolism in the Absence of Atrial Fibrillation. (2019) (15)
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2018) (15)
US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: déjà vu all over again (2018) (15)
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention (2008) (15)
Bicuspid pulmonic valve. (2009) (15)
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. (2017) (14)
Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial (2012) (13)
Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation (2014) (13)
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. (2022) (13)
Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation (2011) (13)
AMERICAN COLLEGE OF CARDIOLOGY, AMERICAN HEART ASSOCIATION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES (2006) FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION (ENDING) (2007) (13)
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. (2019) (13)
Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. (2019) (13)
Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT‐AF and PREVAIL Studies (2019) (13)
Sudden hemodynamic collapse following relief of cardiac tamponade in aortic dissection. (1986) (12)
Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA2 DS2-VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum. (2016) (12)
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (12)
The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an evolution or revolution? (2011) (12)
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial (2016) (12)
Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation (2014) (11)
Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy. (2014) (11)
Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. (2020) (11)
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. (2019) (10)
Femoral pseudoaneurysm following nonpenetrating trauma in a patient with aortic insufficiency. (1985) (10)
Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. (2017) (10)
Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta‐analysis (2018) (10)
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. (2018) (10)
Ineligibility for anticoagulation in patients with atrial fibrillation. (2013) (10)
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. (2014) (10)
Series of Monographs on Venous Thromboembolic Disease (2003) (10)
Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management (2011) (10)
Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial (2019) (10)
Peripheral pulmonary artery stenosis masquerading as pulmonary hypertension: A diagnostic and therapeutic challenge (2012) (9)
Left ventricular thrombus and stroke after myocardial infarction: toward prevention or perplexity? (1989) (9)
Temporal trends in ischemic stroke and anticoagulation therapy for non‐valvular atrial fibrillation: effect of diabetes (2017) (9)
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study (2014) (9)
Current Strategies in the Evaluation and Management of Cocaine-Induced Chest Pain (2015) (9)
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention (2018) (9)
Developed in Collaboration With the European Heart Rhythm Association and the Sudden Cardiac Death) Management of Patients With Ventricular Arrhythmias and the Prevention of Practice Guidelines (Writing Committee to Develop Guidelines for (2007) (9)
Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies. (2007) (8)
Low intraoperative heart rate volatility is associated with early postoperative mortality in general surgical patients: a retrospective case–control study (2016) (8)
Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. (2017) (8)
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up (2020) (8)
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry (2020) (7)
Risks to Reversal of Anticoagulation: The Cardiology Perspective (2016) (7)
Anticoagulation for atrial fibrillation in the elderly. (2005) (7)
Everything counts in large amounts: device-detected atrial high-rate arrhythmias. (2009) (7)
Do Current Guidelines Result in Overuse of Warfarin Anticoagulation in Patients With Atrial Fibrillation? (2009) (7)
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial (2021) (7)
Persistence with Dabigatran Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Gloria-AF Registry (2016) (7)
Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. (2020) (7)
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial (2016) (7)
Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF‐PCI and RE‐DUAL PCI trial (2018) (7)
Warfarin pharmacogenetics: A controlled dose–response study in healthy subjects (2013) (7)
Combining carotid endarterectomy with coronary bypass surgery (2005) (7)
Effect of Discontinuing Dabigatran in Patients with Atrial Fibrillation (From the Dabigatran Cohort of the GLORIA-AF Registry) (2019) (7)
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. (2016) (7)
ANTITHROMBOTIC TREATMENT IN RELATION TO AGE IN PATIENTS WITH NEWLY DIAGNOSED ATRIAL FIBRILLATION IN NORTH AMERICA (GLORIA-AF PHASE II) (2015) (6)
Effect of nitroglycerin during hemodynamic estimation of valve orifice in patients with mitral stenosis. (1987) (6)
Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). (2019) (6)
Prognostic Value of Electrocardiographic QRS Diminution in Patients Hospitalized With COVID-19 or Influenza (2021) (6)
Variability in low-density lipoprotein cholesterol and cardiovascular risk: should consistency be a new target? (2015) (6)
Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial (2011) (6)
Objective quality assessment of atrial fibrillation ablation: a novel scoring system. (2013) (6)
What can ongoing clinical trials of anticoagulants demonstrate? (2009) (6)
Stroke Prevention Guidelines (1995) (6)
Improved scoring system for the electrocardiographic diagnosis of left ventricular hypertrophy (2019) (6)
Percutaneous closure of a patent foramen ovale in left-sided carcinoid heart disease (2007) (6)
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. (2016) (6)
GUIDELINE 2011 ACCF / AHA / HRS Focused Update on the Management of Patients With Atrial Fibrillation ( Updating the 2006 Guideline ) (2010) (6)
Should we use anticoagulation for patients with chronic heart failure? (2006) (5)
Aspirin in elderly atrial fibrillation patients. (1994) (5)
Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation (2013) (5)
Determinants of Hospital Charges and Costs in Acute Myocardial Infarction: A Report from the Myocardial Infarction Cost Study (MICS) Group (1996) (5)
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF (2018) (5)
THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF) (2017) (5)
Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation (2014) (5)
Acute myocardial infarction, special care units, analgesia, and complications. (1990) (5)
Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). (2019) (5)
Sunday, 26 August 2012 (2012) (5)
Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review. (2022) (5)
Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor (2004) (5)
PATTERNS OF NEWLY DETECTED ATRIAL FIBRILLATION AND ANTITHROMBOTIC TREATMENT IN NORTH AMERICA (GLORIA-AF PHASE II) (2015) (5)
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF (2021) (5)
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (4)
Off-pump coronary bypass surgery. (2003) (4)
Abstract 14365: Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF (2012) (4)
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF (2019) (4)
Stroke: Finding atrial fibrillation after cryptogenic stroke (2012) (4)
Abstract 15686: Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke: Results From the ROCKET AF Trial (2014) (4)
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials (2022) (4)
Outcomes of patients with atrial fibrillation and significant valvular lesions: Comparison of the effects of rivaroxaban and warfarin in the ROCKET AF trial (2013) (4)
The Word Heart Federation Roadmap for Nonvalvular Atrial Fibrillation (2017) (4)
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment (2016) (4)
Edinburgh Research Explorer Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation (2015) (4)
Thrombosis in the left ventricle in patients with dilated cardiomyopathy. (1994) (4)
Novel antiplatelet and anticoagulant agents in the cardiac care unit. (2013) (3)
2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee. (2020) (3)
Extraluminal compression of an aortic graft simulating recoarctation. (1987) (3)
Abstract 15879: Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial (2013) (3)
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. (2016) (3)
A COMPARISON OF ATRIAL FIBRILLATION MONITORING STRATEGIES IN PATIENTS AT HIGH RISK FOR ATRIAL FIBRILLATION AND STROKE: RESULTS FROM THE REVEAL AF STUDY (2018) (3)
A Baby in the Bathwater: Preserving Evidence-Based Medicine. (2016) (3)
Unstable angina in a patient with anomalous origin of the left main coronary artery from the right sinus of Valsalva. (2010) (3)
Vorapaxar, combination antiplatelet therapy, and stroke. (2014) (3)
O215 Results of the 1st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants (2014) (3)
GLORIA-AF Investigators: Antithrombotic treatment patterns in 10,871 patients with newly diagnosed non-valvular atrial fibrillation: the GLORIA-AF Registry Program, Phase II (2015) (3)
NOVEL ORAL ANTICOAGULANT AVAILABILITY INCREASES APPROPRIATE USE OF ANTICOAGULANTS FOR NONVALVULAR ATRIAL FIBRILLATION IN CLINICAL PRACTICE (2016) (3)
Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. (2016) (3)
825-2 Efficacy and safety of ximelagatran compared with well-controlled warfarin in women and men with nonvalvular atrial fibrillation in the SPORTIF trials (2004) (3)
OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL (2014) (3)
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry (2022) (3)
Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement (2011) (3)
Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF. (2021) (3)
Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices (2021) (3)
Prognostic Value of Electrocardiographic QRS Diminution in Patients With COVID-19 (2021) (3)
Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia. (2008) (3)
Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?Response to Savino and Halperin (2016) (3)
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program (2022) (2)
Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis: 2 Pathways to a Single Goal. (2021) (2)
Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF (2020) (2)
Abstract 17513: Edoxaban for the Prevention of Thromboembolism in Patients With Bioprosthetic Valves in ENGAGE AF-TIMI 48 (2016) (2)
The ten most commonly asked questions about stroke prevention in atrial fibrillation. (2001) (2)
Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. (2021) (2)
TECHNOLOGY AND PRACTICE EXECUTIVE COMMITTEE (1998) (2)
Anticoagulant therapy: Warfarin sensitivity genotyping closer to clinical practice (2010) (2)
Stroke prevention in atrial fibrillation. (1993) (2)
Systematic Review/Meta-analysis Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials (2014) (2)
Peripheral vascular disease: medical evaluation and treatment. (1987) (2)
Standards and Barriers in Acute Stroke Therapy: A Leap Forward in the Evolution of Endovascular Interventions for Stroke. (2015) (2)
Challenges for the Basis of Practice The Role of Digoxin in the Treatment of Heart Failure (2008) (2)
Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Anticoagulated Patients With Atrial Fibrillation: The HAS-BLED Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in (2012) (2)
Patients With ST-Elevation Myocardial Infarction : 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of (2012) (2)
Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"? (2012) (2)
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL (2013) (2)
Preventing Myocardial Infarction in Patients With Atrial Fibrillation: Another Piece of the Puzzle. (2017) (2)
Ischemic Attack: A Guideline for Healthcare Professionals From the American Guidelines for the Prevention of Stroke in Patients With Stroke or Transient (2011) (2)
Racial and Sex Differences in Stroke Risk in Patients With Atrial Fibrillation. (2019) (2)
Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study (2018) (1)
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF (2021) (1)
Abstract P177: Projected Change in Outpatient Management of Blood Pressure in the United States with the Implementation Of JNC-8 as Compared to JNC-7 Criteria (2016) (1)
Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. (2019) (1)
When Should We Go With HALT? (2016) (1)
Oral Thrombin Inhibition in the Prophylaxis Against Thromboembolism in Non-valvular Atrial Fibrillation Late-breaking results of the Fifth Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF V) Study (2003) (1)
Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery. (1986) (1)
Anticoagulation in Women with Nonvalvular Atrial Fibrillation: Insights from Clinical Trials (2007) (1)
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry. (2020) (1)
Six-month follow-up on patients undergoing a transesophageal echocardiography guided cardioversion from atrial fibrillation The assessment of cardioversion using transesophageal echocardiography (2001) (1)
Cardiac Ultrasound in Stroke Investigation (1997) (1)
PERSISTENCE WITH THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION: THE GLORIA-AF REGISTRY (2017) (1)
Acute effects of oral labetalol on myocardial conduction after coronary artery bypass grafing (1984) (1)
Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to (2013) (1)
Vertebral Artery Disease SVS Guideline on the Management of Patients With Extracranial Carotid and ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/ 2011 (2011) (1)
RATES OF STROKE AND BLEEDING WITH DABIGATRAN 150 AND 110 MG BID IN CLINICAL PRACTICE: THE GLORIA-AF REGISTRY (2017) (1)
Transesophageal Echocardiography in High-Risk Patients with Atrial Fibrillation (1998) (1)
Stroke Prevention in Atrial Fibrillation. Findings from the GLORIA-AF Registry (2020) (1)
Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation with Inserted Cardiac Monitors. (2021) (1)
1046-165 Measurement of resting ankle branchial index may not accurately identify disease in patients with signs or symptoms of peripheral arterial disease (2004) (1)
Efficacy and safety of amiodarone in patients with atrial fibrillation in the era of target-specific anticoagulants. (2014) (1)
P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy (2017) (1)
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness (2022) (1)
P281Baseline characteristics of patients with atrial fibrillation with and without comorbid heart failure: the GLORIA-AF registry (2017) (1)
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial (2022) (1)
Age, Ethnicity, and Stroke Risk in Patients With Atrial Fibrillation: Another Stitch in the Patchwork. (2015) (1)
THE USE OF DUAL ANTIPLATELET THERAPY AND PATIENT OUTCOMES IN THOSE UNDERGOING PCI IN THE ROCKET AF TRIAL (2014) (1)
Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation (2021) (1)
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older (2021) (1)
Determinants of survival and clinical response in heart failure patients treated with captopril (1982) (1)
P3590Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudy (2017) (1)
P2887Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry (2018) (1)
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF (2021) (1)
Antithrombotic Therapy for Patients with Atrial Fibrillation (2018) (1)
Abstract 16840: Predictors of Hospitalization in Patients With Atrial Fibrillation: An Analysis From ROCKET AF (2014) (1)
Cardiology/American Heart Association Task Force on Practice Guidelines and 2011 ACCF/AHA/HRS Recommendations): A Report of the American College of Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC (2014) (1)
Halperin and Fuster Patent Foramen Ovale and Recurrent Stroke 2581 (2002) (1)
Prevention of deep venous thrombosis and pulmonary embolism in surgical patients. (1991) (1)
P6112Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial (2017) (1)
P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial (2017) (1)
RISK FACTORS FOR PROGRESSION OF MITRAL ANNULUS CALCIFICATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (2012) (1)
Independent Predictors of Mortality in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF (2012) (1)
Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Review (2013) (1)
P4799When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry (2018) (1)
Fibrillation : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial (2012) (1)
Prevention of embolism in atrial fibrillation (1991) (1)
PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY (2017) (1)
Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring. (2023) (1)
industry-sponsored clinical trials: the ARO-CRO model Improving academic leadership and oversight in large (2011) (0)
Podium Presentations 1 A REDUCTION IN EJECTION FRACTION DURING STRESS WITHIN THE NORMAL RANGE WITH GATED SPECT IMAGING IS NOT ASSOCIATED WITH INCREASED MORTALITY (2010) (0)
QUANTITATIVE PHARMACOGENOMICS OF THE ANTICOAGULANT RESPONSE TO WARFARIN IN HEALTHY SUBJECTS (2011) (0)
Abstract 13565: Patterns of Newly Detected Atrial Fibrillation and Antithrombotic Treatment in GLORIA-AF Phase II (2015) (0)
Safety of Left Atrial Appendage Closure in Patients with Low Ejection Fraction (2015) (0)
GW29-e1538 Two-year safety and effectiveness of dabigatran in Asian patients with atrial fibrillation: Phase II results from Asian countries in the GLORIA-AF Registry Program (2018) (0)
University of Birmingham Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: (2018) (0)
Practice Guidelines 2010 Accf/aha Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults a Report of the American College of Cardiology Foundation/american Heart Association Task Force on Practice Guidelines ¶ ¶recused from Voting on Section 2.4.2, Recommendations for Measurement of (0)
Three‐dimensional echocardiography demonstrates a skewered left ventricular thrombus in a patient with a heart transplant (2018) (0)
OPTICAL COHERENCE TOMOGRAPHY OF CULPRIT LESIONS IN PATIENTS WITH PRIOR CEREBROVASCULAR EVENTS COMPARED TO CONTROLS (2017) (0)
Treatment of Hypertrophic Cardiomyopathy (2011) (0)
Atrial Fibrillation and Stroke Concepts and Controversies Comments, Opinions, and Reviews (2001) (0)
Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial (2014) (0)
Characterisation of Access Site Versus Non-Access Site Bleeding After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation (2018) (0)
Patients With Stroke and Transient Ischemic Attack Update to the AHA/ASA Recommendations for the Prevention of Stroke in (2009) (0)
ACC expert consensus document on ethical coding and billing practices for cardiovascular medicine specialists11“Ethical Coding and Billing Practices for Cardiovascular Medicine Specialists” was approved by the American College of Cardiology Board of Trustees on October 24, 1998. (1999) (0)
P5139Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial (2018) (0)
Chapter 48 – Raynaud's Phenomenon (2006) (0)
Anticoagulation Therapy for Atrial Fibrillation in Patients with Implanted Cardiac Arrhythmia Devices (2011) (0)
Barry A Love therapeutic challenge Peripheral pulmonary artery stenosis masquerading as pulmonary hypertension : A diagnostic and (2012) (0)
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. (2021) (0)
Thrombocytopenia during heparin therapy: a clinical conundrum (2008) (0)
Abstract 153: Heart Rate Volatility as a Predictor for Mortality Within 48 Hours After Surgical Procedure (2014) (0)
The Role of and Selection Process for the New Anticoagulants in Nonvalvular Atrial Fibrillation (2020) (0)
Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial (2015) (0)
TCT-163 Do Patients with Paroxysmal Atrial Fibrillation in Sinus Rhythm during PCI Require Triple Therapy? Results from a Multicenter Center Study (2013) (0)
P4600Prescribing of dabigatran etexilate in accordance with the European label for stroke prevention in atrial fibrillation: Findings from the GLORIA-AF Registry (2017) (0)
Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassiﬁcation Integrated Discrimination Improvement (2011) (0)
Low-Dose Anticoagulation for Atrial Fibrillation: When Is a Floor a Trap Door? (2021) (0)
Abstract 1571: Association of Chronic Kidney Disease With Atrial Fibrillation in the United States (2009) (0)
CardioPulse Articles. (2016) (0)
Gender-based differences in rates of thromboembolism and bleeding in randomized trials In the Stroke Prevention using an Oral (2007) (0)
Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention AF-PCI (2018) (0)
RELATIONSHIPS BETWEEN LEFT VENTRICULAR MASS AND AORTIC VALVE CALCIFICATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (2010) (0)
Prevention of stroke in patients with atrial ﬁbrillation: current strategies and future directions (2008) (0)
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial (2021) (0)
B-PO01-082 ARTIFICIAL INTELLIGENCE-ASSISTED QRS AMPLITUDE ANALYSIS OF THE PRESENTING ELECTROCARDIOGRAM PREDICTS MORTALITY IN COVID-19 (2021) (0)
Challenges for the Basis of Practice Should We Use Outpatient Dobutamine or Milrinone (2009) (0)
Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial (2019) (0)
Use of IIb/IIIa inhibitors in patients with acute coronary syndromes who do not undergo percutaneous coronary intervention (2002) (0)
Unstable angina: coronary angioplasty and bypass surgery (1989) (0)
P2896Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF (2018) (0)
Abstract 18121: Extracranial Systemic Embolic Events in Patients With Atrial Fibrillation: Incidence and Outcomes (2013) (0)
Abstract 15083: Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2016) (0)
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events (2017) (0)
Abstract 15096: Electrocardiographic QRS Amplitude Predicts Mortality in Hospitalized Patients With CoViD-19 (2020) (0)
SEX DIFFERENCES IN ANTITHROMBOTIC THERAPY: OBSERVATIONS FROM THE GLORIA-AF REGISTRY PROGRAM (2016) (0)
Abstract 18905: Novel Oral Anticoagulant Availability Increases Appropriate Use of Anticoagulants for Nonvalvular Atrial Fibrillation in the Elderly Aged >= 75 Years Old in Clinical Practice (2016) (0)
1460Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial (2018) (0)
Appendage System for Embolic Protection in Patients With Atrial Fibrillation ) Trial Atrial Fibrillation : 2 . 3-Year Follow-up of the PROTECT AF ( Watchman Left Atrial Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With (2013) (0)
THE GLOBAL REGISTRY PROGRAM ON LONG-TERM ORAL ANTI-THROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION (GLORIA-AF): FIRST ASSESSMENT OF BASELINE CHARACTERISTICS OF DABIGATRAN AND VKA COHORTS IN NORTH AMERICA (2014) (0)
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (0)
Abstract TP428: Antithrombotic Therapy in Patients With Atrial Fibrillation and Prior Stroke in GLORIA- AF Phase II (Global Registry on Long-term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation, Phase II) (2016) (0)
Coronary Artery Disease and Peripheral Vascular Disease (1996) (0)
Safety and effectiveness of dabigatran in patients with atrial fibrillation with and without prior stroke: Data from the gloria-af registry program (2018) (0)
Introduction (2003) (0)
Estimated risk of deep venous thrombosis among Chinese patients admitted to general medical wards (2004) (0)
Jay D. Coffman, MD 1928–2006 (2007) (0)
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". (2016) (0)
P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis (2019) (0)
Preoperative assessment and preparation of the urological patient. The patient with cardiac disease. (1992) (0)
Associations of Left Ventricular Hypertrophy with Prevalent and Incident Valve Calcification: The Multi-Ethnic Study of Atherosclerosis (2012) (0)
Acute Limb Ischemia (2003) (0)
Abstract 12569: Analysis of Deep Learning Models for Prediction of Heart Failure Mortality (2020) (0)
Abstract 17226: Latin American Patients With Atrial Fibrillation Have a Higher Risk Profile but Similar Response With Rivaroxaban versus Warfarin: A ROCKET AF Substudy (2017) (0)
Epidemiology of Claudication (2002) (0)
P3622Timing of trial stoppage for non-inferiority trials and interpretation: lessons from ROCKET AF (2017) (0)
PM198 Antithrombotic Treatment in Relation to Age and Stroke Risk in Patients With Newly Diagnosed Atrial Fibrillation (Gloria-AF Phase II) (2016) (0)
Abstract 13775: Dual vs. Triple Antithrombotic Therapy After Coronary Stenting in Patients With Non-Valvular Atrial Fibrillation (2013) (0)
University of Birmingham Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion (2018) (0)
Abstract 19389: The Net Clinical Benefit of Left Atrial Appendage Closure in the Continued Access Protocol (CAP) Registry (2012) (0)
Wednesday, 29 August 2012 (2012) (0)
PHYSICIAN CHOICE OF DISCHARGE ANTITHROMBOTIC REGIMEN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION BASED ON BLEEDING AND ISCHEMIC RISK ASSESSMENT: RESULTS FROM AVIATOR MULTI-CENTER REGISTRY (2014) (0)
Is there a role for troponin-I in the risk stratification of stable asymptomatic hemodialysis patients? (2002) (0)
Anticoagulant selection in relation to the SAMe-TT 2 R 2 score in patients with atrial ﬁ brillation: The GLORIA-AF registry Hellenic Journal of Cardiology (2021) (0)
IMPACT OF LEFT VENTRICULAR DYSFUNCTION ON OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE AVIATOR REGISTRY (2015) (0)
Antithrombotic therapy for atrial fibrillation: Balancing the risks (2002) (0)
Adjusted Dose Vitamin-K Antagonist , Comparing Efficacy and Safety With Unadjusted (2008) (0)
Presidential address (2002) (0)
P5140Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIA-AF registry program (2018) (0)
Response: “Actually, it’s more of a guideline than a rule”. (2015) (0)
Aortic and Arterial Aneurysms (2003) (0)
Presidential address (2003) (0)
P3862A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics (2018) (0)
200Safety of uninterrupted dabigatran in cardiovascular interventions in the GLORIA-AF registry program (2018) (0)
Abstract 15601: Increased Left Ventricular Mass Predicts Incident Aortic and Mitral Valve Calcification: The Multi-Ethnic Study of Atherosclerosis (2010) (0)
Association Between Stable Coronary Artery Disease and Hospital Readmissions Following Catheter Ablation for Atrial Fibrillation. (2023) (0)
No conflict of interest in data monitoring (2018) (0)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation the Investigators* (0)
Abstract 10703: Does CHADS2 Score Predict Atrial Arrhythmias? (2012) (0)
Abstract 16169: Individual and Regional Determinants of Time in Therapeutic Range Among Patients Randomized to Warfarin in the ROCKET AF Trial of Rivaroxaban (2011) (0)
Abstract 16046: Clinical Action is Frequently Taken Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor in High Risk Patients: The REVEAL AF Study (2017) (0)
Jay Denton Coffman, MD (2007) (0)
Novel Oral Anticoagulants (2010) (0)
Peripheral Vascular Disease and Dilated Aorta (2010) (0)
Effect oflabetalol onlimbhaemodynamics inpatients following coronary artery bypass graft surgery (1986) (0)
Prevention of left ventricular mural thrombosis and arterial embolism during and after acute myocardial infarction (1990) (0)
Abstract 1647: Bisphosphonate Use and the Prevalence of Cardiovascular Calcification in Women: The Multi-Ethnic Study of Atherosclerosis (2009) (0)
Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of : Antithrombotic Therapy and Prevention of Antithrombotic Therapy for Atrial Fibrillation (2012) (0)
Atrial Fibrillation and Flutter (2013) (0)
Abstract 17137: Renal Dysfunction is a Potent Predictor of Stroke and Systemic Embolism Among Individuals with Atrial Fibrillation: Results from the ROCKET AF Trial (2011) (0)
Peripheral arterial and venous responses to acetylstrophanthidin in patients with acute myocardial infarction (1982) (0)
Taking TASC to TASK: Evolving from nomenclature to guidelines (2015) (0)
OC11_04 Antithrombotic Therapy in Relation to Symptoms in Patients With Atrial Fibrillation: Observations From The Gloria-AF Registry Program (2016) (0)
Abstract 19020: Brief Hand-Held Echocardiography Teaching Improves Diagnosis of Valvular Heart Disease by Medical Students: A Controlled Study in the 2nd Year Cardiovascular Curriculum (2014) (0)
Cardiology Fellowship Program Director Wellness: The Future Depends on it. (2021) (0)
The Society for Vascular Medicine and Biology (1999) (0)
Embracing a new paradigm to sustain vascular medicine. (2003) (0)
Reply: therapeutic goals in patients with acute aortic dissection: management before surgery. (2015) (0)
Abstract 19512: Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation (2017) (0)
IMPACT Study: Rhythm-Guided Anticoagulation Therapy Did Not Improve Outcomes (2014) (0)
2011 ASA/ACCF/AHA/AANN/AAN S/ACR/ASNR/CN S/SAIP/ patients with extracranial carotid and vertebral artery disease (2013) (0)
Unilateral neck pulsations in a patient with a permanent pacemaker. (1985) (0)
Transient Ischemic Attack : A Statement for Healthcare Professionals From the Guidelines for Prevention of Stroke in Patients With Ischemic Stroke (2006) (0)
DIFFERENTIATING LEFT VENTRICULAR ANEURYSM FROM PSEUDOANEURYSM: COMPLEX MULTIDISCIPLINARY AND MULTIMODALITY IMAGING APPROACH TO DIAGNOSIS AND MANAGEMENT (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jonathan Lee Halperin?

Jonathan Lee Halperin is affiliated with the following schools: